Schreiner MediPharm, a German specialty label developer, is one of eight founding members of the Alliance to Zero, a non-profit partnership whose goal is to improve sustainability throughout the pharmaceutical supply chain. The other seven members include Dätwyler, Harro Höfliger, HealthBeacon, Körber Pharma, SCHOTT, Sharp and Ypsomed, a lineup of component suppliers, machine manufacturers and assembly/manufacturing service providers, manufacturers of primary and secondary packaging, and companies responsible for final product assembly or handling products that have been returned after use.
Launched in June, the initiative is designed to support pharma and biotech firms as they shift to net-zero emissions, with the Paris Climate Agreement as a guide. The Alliance aims to launch net-zero pharma products in regulated markets by 2030 at the latest, and the founding members have committed to developing a joint net-zero offering by 2026 to provide pharma companies ample time to finalize their overall product on this basis.
The non-profit has developed a roadmap for a net-zero emissions concept in order for this to be accomplished. The proper steps and language are being developed, while principles are currently being defined, as it refers to tracking the emissions footprint of pharma end products. In addition, the Alliance has plans in the works to collaborate with academic and non-profit organizations pursuing similar goals.